Sai Life Sciences Boosts Production Power with Bidar Unit IV Expansion

Sai Life Sciences has officially commenced commercial operations at Phase II of its Unit IV facility in Bidar, Karnataka, as of June 19, 2025. This phase adds approximately 91 kilolitres (kL) of production capacity, completing the company’s planned expansion of around 195 kL as outlined in its prospectus.

With the completion of this phase, Unit IV now has a total installed capacity of about 640 kL. The expanded facility is equipped to manufacture registered starting materials (RSMs), intermediates, and active pharmaceutical ingredients (APIs) for both clinical trials and commercial supply, supporting the company’s growing role in the global pharmaceutical supply chain.

Headquartered in Hyderabad, Sai Life Sciences is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO). The company partners with pharmaceutical and biotech innovators worldwide to accelerate the discovery, development, and commercialization of new drug candidates, offering integrated services in medicinal chemistry, process development, and scalable manufacturing.

News by Rahul Yelligetti.